Bioreductive activation and drug chaperoning in cobalt pharmaceuticals
- 1 January 2007
- journal article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- No. 36,p. 3983-3990
- https://doi.org/10.1039/b707121c
Abstract
The potential for cobalt(III) complexes in medicine, as chaperones of bioactive ligands, and to target tumours through bioreductive activation, has been examined over the past 20 years. Despite this, chemical properties such as reduction potential and carrier ligands required for optimal tumour targeting and drug delivery have not been optimised. Here we review the chemistry of cobalt(III) drug design, and recent developments in the understanding of the cellular fate of these drugs.This publication has 67 references indexed in Scilit:
- Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit modelBMC Ophthalmology, 2006
- Herpes Simplex Virus Type 1 Entry Is Inhibited by the Cobalt Chelate Complex CTC-96Journal of Virology, 2001
- Efficacy of Cobalt Chelates in the Rabbit Eye Model for Epithelial Herpetic KeratitisCornea, 1998
- Spectroscopy and Electrochemistry of Cobalt(III) Schiff Base ComplexesInorganic Chemistry, 1997
- Topical CTC-96 accelerates wart growth in rabbits infected with cottontail rabbit papillomavirusAntiviral Research, 1994
- The influence of superoxide scavenging compound CTC 23 on type II collagen-induced arthritis in miceInflammation Research, 1992
- THE BIOLOGICAL ACTIONS OF 1,10‐PHENANTHROLINE AND 2,2′‐BIPYRIDINE HYDROCHLORIDES, QUATERNARY SALTS AND METAL CHELATES AND RELATED COMPOUNDSImmunology & Cell Biology, 1969
- Effect of Inorganic Complex Ions on Transmission at a Neuromuscular JunctionNature, 1957
- Biological Activity of Complex Ions Mechanism of Inhibition of AcetylcholinesteraseAustralian Journal of Biological Sciences, 1956
- Biological Activity of Complex IonsNature, 1952